In in vivo experiments, birabresib significantly reduced the tumor volume of HCT116 SMAD4−/− xenografts, while it did not affect the growth of HCT116 SMAD4+/+ xenografts, further supporting the synthetic lethal interaction between BET inhibition and SMAD4 loss. Here, SMAD4 is linked to neoplasm.